Etiology and Risk Factors in Patients with Vulvovaginal Candidiasis in Abidjan (Côte d'Ivoire)
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Limited data on the molecular identification of vulvovaginal candidiasis (VVC) pathogenesis in Côte d'Ivoire are available. Objective: We sought to update the data on the causes of VVC in Abidjan, Côte d'Ivoire. Methods: Conducted between May 2023 and January 2024, this cross-sectional study focused on patients with symptoms suggestive of VVC in Abidjan. Each patient underwent swab collection, direct examination, and culture. Candida chromatic agar and Auxacolor®-based identification tests were performed. A molecular-based polymerase chain reaction (PCR) targeting the hyphal wall protein 1 (hwp1) gene was used to differentiate between C. albicans, C. africana, and C. dubliniensis. Results: The overall prevalence of fungal VVC was 53.6% (222/414 patients). After PCR, no C. africana or C. dubliniensis were observed. C. albicans isolates exhibited two PCR profiles: 941 bp and 941+850 bp, with C. albicans being the most frequently isolated species (70.7%) after C. tropicalis (9.9%). The most affected groups were patients younger than 25 (p = 0.018), those living in precarious housing (p < 0.0001), and pregnant women (p = 0.006). In addition, the presence of vulvovaginal candidiasis was significantly associated with vaginal irrigation (i.e., douching) frequency (p = 0.003), douche used (e.g., antibacterial or not) (p = 0.003), and underwear type (p = 0.037). The most common symptom reported was vaginal itching (46.4%). Conclusion: No strains of C. africana and C. dubliniensis were found. The increased prevalence of VVC in Abidjan warrants further studies.
Abstract
Background: Limited data on the molecular identification of vulvovaginal candidiasis (VVC) pathogenesis in Côte d'Ivoire are available. Objective: We sought to update the data on the causes of VVC in Abidjan, Côte d'Ivoire. Methods: Conducted between May 2023 and January 2024, this cross-sectional study focused on patients with symptoms suggestive of VVC in Abidjan. Each patient underwent swab collection, direct examination, and culture. Candida chromatic agar and Auxacolor®-based identification tests were performed. A molecular-based polymerase chain reaction (PCR) targeting the hyphal wall protein 1 (hwp1) gene was used to differentiate between C. albicans, C. africana, and C. dubliniensis. Results: The overall prevalence of fungal VVC was 53.6% (222/414 patients). After PCR, no C. africana or C. dubliniensis were observed. C. albicans isolates exhibited two PCR profiles: 941 bp and 941+850 bp, with C. albicans being the most frequently isolated species (70.7%) after C. tropicalis (9.9%). The most affected groups were patients younger than 25 (p = 0.018), those living in precarious housing (p < 0.0001), and pregnant women (p = 0.006). In addition, the presence of vulvovaginal candidiasis was significantly associated with vaginal irrigation (i.e., douching) frequency (p = 0.003), douche used (e.g., antibacterial or not) (p = 0.003), and underwear type (p = 0.037). The most common symptom reported was vaginal itching (46.4%). Conclusion: No strains of C. africana and C. dubliniensis were found. The increased prevalence of VVC in Abidjan warrants further studies.
참고문헌 (42)
- Pereira LC, "Vulvovaginal candidiasis and current perspectives : new risk factors and laboratory diagnosis by using MALDI TOF for identifying species in primary infection and recurrence", Eur J Clin Microbiol Infect Dis, 40, pp.1681~1693 (2021)
- Chassot F, "Can intrauterine contraceptive devices be a Candida albicans reservoir?", Contraception, 77, pp.355~359 (2008)
- Anderson MR, "Evaluation of vaginal complaints", JAMA, 291, pp.1368~1379 (2004)
- Nyirjesy P, "Vulvovaginal candidiasis", Obstet Gynecol Clin North Am, 30, pp.671~684 (2003)
- Amouri I, "La candidose vulvovaginale : revue", J Mycol Med, 20, pp.108~115 (2010)
- Sustr V, "Vulvovaginal candidosis : current concepts, challenges and perspectives", J Fungi(Basel), 6, pp.267~ (2020)
- Phillips NA, "Topical treatment of recurrent vulvovaginal candidiasis : an expert consensus", Womens Health Rep(New Rochelle), 3, pp.38~42 (2022)
- Foxman B, "Prevalence of recurrent vulvovaginal candidiasis in 5European countries and the United States : results from an internet panel survey", J Low Genit Tract Dis, 17, pp.340~345 (2013)
- Pfaller MA, "Epidemiology of invasive candidiasis : a persistent public health problem", Clin Microbiol Rev, 20, pp.133~163 (2007)
- Charsizadeh A, "Microbial epidemiology of candidaemia in neonatal and paediatric intensive care units at the Children's Medical Center, Tehran", Mycoses, 61, pp.22~29 (2018)
- Borman AM, "Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom", J Clin Microbiol, 51, pp.967~972 (2013)
- Romeo O, "First molecular method for discriminating between Candida africana, Candida albicans, and Candida dubliniensis by using hwp1 gene", Diagn Microbiol Infect Dis, 62, pp.230~233 (2008)
- Sullivan DJ, "Candida dubliniensis sp. nov. : phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals", Microbiology(Reading), 141(Pt 7), pp.1507~1521 (1995)
- Romeo O, "Candida africana and its closest relatives", Mycoses, 54, pp.475~486 (2011)
- Odds FC, "Molecular phylogenetics of Candida albicans", Eukaryot Cell, 6, pp.1041~1052 (2007)
- Grigoriou O, "Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors", Eur J Obstet Gynecol Reprod Biol, 126, pp.121~125 (2006)
- Konaté A, "Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan(Côte d'Ivoire)", J Mycol Med, 24, pp.93~99 (2014)
- Djohan V, "Sensibilité in vitro des souches de Candida albicans d'origine vaginale aux antifongiques àAbidjan(Côte d'Ivoire)", J Mycol Med, 22, pp.129~133 (2012)
- Djohan V, "Recurrent vulvovaginal candidiasis in Abidjan(Côte d'Ivoire) : Aetiology and associated factors", J Mycol Med, 29, pp.127~131 (2019)
- Angora KE, "Susceptibility of Candida species isolated from recurrent vulvovaginal candidiasis to antifungal agents among women at Institut Pasteur of Côte d'Ivoire", J Yeast Fungal Res, 9, pp.21~26 (2018)
- Dieng Y, "Identification de trois souches de Candida africana au Sénégal", J Mycol Med, 22, pp.335~340 (2012)
- Disha T, "Prevalence and risk factors of vulvovaginal candidosis during pregnancy : a review", Infect Dis Obstet Gynecol, 2022, pp.6195712~ (2022)
- Aguin TJ, "Vulvovaginal candidiasis in pregnancy", Curr Infect Dis Rep, 17, pp.30~ (2015)
- Jeanmonod R, "StatPearls" (2023), StatPearls Publishing
- Ngouana TK, "Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicans isolates from Yaoundé HIV-infected patients", Med Mycol, 55, pp.546~554 (2017)
- Tietz HJ, "Candida africana sp. nov., a new human pathogen or a variant of Candida albicans?", Mycoses, 44, pp.437~445 (2001)
- Loreto ES, "Candida dubliniensis : epidemiology and phenotypic methods for identification", Mycopathologia, 169, pp.431~443 (2010)
- Nikmanesh B, "Candida africana and Candida dubliniensis as causes of pediatric candiduria : A study using HWP1 gene size polymorphism", AIMS Microbiol, 6, pp.272~279 (2020)
- Gharehbolagh SA, "Distribution, antifungal susceptibility pattern, and intra-Candida albicans species complex prevalence of Candida africana : A systematic review and meta-analysis", PLoS ONE, 15, pp.e0237046~ (2020)
- Rezazadeh E, "Use of costeffective and rapid molecular tools for identification of Candida species, opportunistic pathogens", Curr Med Mycol, 2, pp.1~4 (2016)
- Sharifynia S, "In vitro antifungal susceptibility profiles of Candida albicans complex isolated from patients with respiratory infections", Acta Med Iran, 54, pp.376~381 (2016)
- Makanjuola O, "An update on the roles of non-albicans Candida species in vulvovaginitis", J Fungi(Basel), 4, pp.121~ (2018)
- Bitew A, "Vulvovaginal candidiasis : species distribution of Candida and their antifungal susceptibility pattern", BMC Womens Health, 18, pp.94~ (2018)
- Butler G, "Evolution of pathogenicity and sexual reproduction in eight Candida genomes", Nature, 459, pp.657~662 (2009)
- Jackson ST, "The epidemiology of mycotic vulvovaginitis and the use of antifungal agents in suspected mycotic vulvovaginitis and its implications for clinical practice", West Indian Med J, 54, pp.192~195 (2005)
- Kalia N, "Prevalence of vulvovaginal infections and species-specific distribution of vulvovaginal candidiasis in married women of North India", Int J Curr Microbiol App Sci, 4, pp.253~266 (2015)
- Kunzelmann V, "Prerequisites for effective therapy of chronic recurrent vaginal candidiasis", Mycoses, 39(Suppl 1), pp.65~72 (1996)
- Richter SS, "Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases", J Clin Microbiol, 43, pp.2155~2162 (2005)
- Cooke G, "Treatment for recurrent vulvovaginal candidiasis(thrush)", Cochrane Database Syst Rev, 1, pp.CD009151~ (2022)
- Sobel JD, "Recurrent vulvovaginal candidiasis", Am J Obstet Gynecol, 214, pp.15~21 (2016)
- de Leon EM, "Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes", BMC Infect Dis, 2, pp.1~ (2002)
- Benchellal M, "La candidose vulvo-vaginale àl'hôpital militaire d'instruction Mohammed V(Maroc)", J Mycol Med, 21, pp.106~112 (2011)